• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

多发性骨髓瘤治疗选择中心脏毒性结局的风险平衡：伊沙佐米、来那度胺和地塞米松（IRd）对比卡非佐米、来那度胺和地塞米松（KRd）的回顾性多中心评估

Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd).

作者信息

Lee Benjamin J, Sayer Michael, Naqvi Ali A, Mai Karen T, Patel Pranav M, Lee Lisa X, Ozaki Aya F

机构信息

Department of Pharmacy Chao Family Comprehensive Cancer Center University of California Irvine Health Orange California USA.

Department of Clinical Pharmacy Practice School of Pharmacy & Pharmaceutical Sciences University of California Irvine California USA.

出版信息

EJHaem. 2025 Apr 28;6(3):e70038. doi: 10.1002/jha2.70038. eCollection 2025 Jun.

DOI:10.1002/jha2.70038
PMID:40297748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12036692/
Abstract

INTRODUCTION

Carfilzomib use has been extensively associated with cardiovascular toxicity; the risk with ixazomib, a novel oral proteasome inhibitor, is underreported and no large comparative analysis is available.

METHODS

We conducted a retrospective cohort study utilizing the TriNetX platform to compare toxicity outcomes among multiple myeloma patients who received lenalidomide, dexamethasone, and ixazomib (IRd) or carfilzomib (KRd).

RESULTS

After propensity-score-matching 478 patients from each cohort, the onset of new heart failure (HR 0.25; < 0.001) and arrhythmias (HR 0.57; = 0.014) at 6 months were significantly lower with IRd while overall survival at 3 years was similar ( = 0.50).

CONCLUSION

IRd is associated with a significantly lower risk of cardiac toxicities compared to KRd.

摘要

引言

卡非佐米的使用与心血管毒性广泛相关；新型口服蛋白酶体抑制剂伊沙佐米的相关风险报道较少，且尚无大型对比分析。

方法

我们利用TriNetX平台进行了一项回顾性队列研究，以比较接受来那度胺、地塞米松和伊沙佐米（IRd）或卡非佐米（KRd）的多发性骨髓瘤患者的毒性结果。

结果

在对每个队列中的478例患者进行倾向评分匹配后，IRd组在6个月时新发心力衰竭（HR 0.25；<0.001）和心律失常（HR 0.57；=0.014）的发生率显著较低，而3年总生存率相似（=0.50）。

结论

与KRd相比，IRd发生心脏毒性的风险显著更低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3973/12036692/6cbaba21bdfa/JHA2-6-e70038-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3973/12036692/b347c59ed2a1/JHA2-6-e70038-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3973/12036692/6cbaba21bdfa/JHA2-6-e70038-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3973/12036692/b347c59ed2a1/JHA2-6-e70038-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3973/12036692/6cbaba21bdfa/JHA2-6-e70038-g001.jpg

相似文献

1
Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd).多发性骨髓瘤治疗选择中心脏毒性结局的风险平衡：伊沙佐米、来那度胺和地塞米松（IRd）对比卡非佐米、来那度胺和地塞米松（KRd）的回顾性多中心评估
EJHaem. 2025 Apr 28;6(3):e70038. doi: 10.1002/jha2.70038. eCollection 2025 Jun.
2
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.卡非佐米或硼替佐米联合来那度胺和地塞米松治疗无即刻自体干细胞移植意向的新诊断多发性骨髓瘤患者（ENDURANCE）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
3
Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.伊沙佐米、来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤疗效的网状Meta分析
Hematology. 2023 Dec;28(1):2156731. doi: 10.1080/16078454.2022.2156731.
4
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.卡非佐米联合环磷酰胺和地塞米松或来那度胺和地塞米松联合自体移植，或卡非佐米联合来那度胺和地塞米松，随后用卡非佐米联合来那度胺或来那度胺维持治疗新诊断的多发性骨髓瘤患者（FORTE）：一项随机、开放标签、2 期试验。
Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.
5
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.卡非佐米用于新诊断的多发性骨髓瘤患者的诱导、巩固及维持治疗，伴或不伴自体干细胞移植：随机2期FORTE试验的预设计细胞遗传学亚组分析
Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.
6
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.比较在美国用于治疗复发/难治性多发性骨髓瘤患者的常用蛋白酶体抑制剂-免疫调节剂药物三联方案的医疗成本和资源利用情况。
J Manag Care Spec Pharm. 2023 Nov;29(11):1205-1218. doi: 10.18553/jmcp.2023.23031. Epub 2023 Sep 30.
7
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.在 III 期 ASPIRE 研究中，接受卡非佐米、来那度胺和地塞米松（KRd）与来那度胺和地塞米松（Rd）治疗的复发性多发性骨髓瘤患者，根据计划治疗持续时间的反应和无进展生存期。
J Hematol Oncol. 2018 Apr 4;11(1):49. doi: 10.1186/s13045-018-0583-7.
8
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.在常规临床实践中，来那度胺和地塞米松（Rd）与伊沙佐米、来那度胺和地塞米松（IRD）相比，对复发和难治性多发性骨髓瘤患者的生存获益。
BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1.
9
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.美国复发/难治性多发性骨髓瘤（RRMM）中硼替佐米（B）、卡非佐米（C）、达雷妥尤单抗（D）或伊沙佐米（I）三联方案的真实世界疗效比较。
Ann Hematol. 2021 Sep;100(9):2325-2337. doi: 10.1007/s00277-021-04534-8. Epub 2021 May 10.
10
Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.来那度胺/地塞米松为基础的三联方案治疗美国复发性和/或难治性多发性骨髓瘤的疗效比较：真实世界电子健康记录数据的分析。
Curr Probl Cancer. 2024 Jun;50:101078. doi: 10.1016/j.currproblcancer.2024.101078. Epub 2024 Mar 27.

本文引用的文献

1
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma.多发性骨髓瘤患者的报告不良事件和早期治疗中断。
JAMA Netw Open. 2024 Mar 4;7(3):e243854. doi: 10.1001/jamanetworkopen.2024.3854.
2
The EASEMENT study: A multicentre, observational, cross-sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable-containing or fully oral therapies.EASEMENT 研究：一项多中心、观察性、横断面研究，旨在评估接受含注射剂或全口服治疗的多发性骨髓瘤患者的患者偏好、治疗满意度、生活质量和医疗资源利用情况。
Eur J Haematol. 2024 Jun;112(6):889-899. doi: 10.1111/ejh.14180. Epub 2024 Feb 23.
3
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
比较在美国用于治疗复发/难治性多发性骨髓瘤患者的常用蛋白酶体抑制剂-免疫调节剂药物三联方案的医疗成本和资源利用情况。
J Manag Care Spec Pharm. 2023 Nov;29(11):1205-1218. doi: 10.18553/jmcp.2023.23031. Epub 2023 Sep 30.
4
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.硼替佐米、来那度胺和地塞米松（VRd）与卡非佐米、来那度胺和地塞米松（KRd）作为新诊断多发性骨髓瘤的诱导治疗。
Blood Cancer J. 2023 Jul 25;13(1):112. doi: 10.1038/s41408-023-00882-y.
5
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.来那度胺联合伊沙佐米和地塞米松治疗不适合移植的新诊断多发性骨髓瘤患者。
Blood. 2021 Jul 1;137(26):3616-3628. doi: 10.1182/blood.2020008787.
6
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.多发性骨髓瘤患者临床试验以外的治疗管理：了解疗效、安全性和耐受性以及生活质量之间的平衡。
Blood Cancer J. 2021 Feb 18;11(2):40. doi: 10.1038/s41408-021-00432-4.
7
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.卡非佐米、来那度胺和地塞米松联合移植治疗新诊断的多发性骨髓瘤。
Blood. 2020 Nov 26;136(22):2513-2523. doi: 10.1182/blood.2020007522.
8
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.来那度胺、伊沙佐米和地塞米松联合治疗多发性骨髓瘤。
N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
9
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.新诊断多发性骨髓瘤患者的持续治疗与固定疗程治疗的比较。
J Clin Oncol. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17.
10
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.在 III 期 VISTA 研究中，接受硼替佐米-美法仑-泼尼松治疗的多发性骨髓瘤患者中，硼替佐米累积剂量对生存的影响。
Am J Hematol. 2015 Apr;90(4):314-9. doi: 10.1002/ajh.23933. Epub 2015 Feb 27.